wpengine

This is the "wpengine" admin user that our staff uses to gain access to your admin area to provide support and troubleshooting. It can only be accessed by a button in our secure log that auto generates a password and dumps that password after the staff member has logged in. We have taken extreme measures to ensure that our own user is not going to be misused to harm any of our clients sites.

Using lasers to paint a high-definition picture of the body’s COVID-19 immune response

Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application.

In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many other companies, Adarza found itself having to shift its strategy as the SARS-CoV-2 pandemic shut down non-essential businesses across the economy. Instead of launching the system with its planned focus on immuno-oncology and neurology, the firm has moved to use its technology for immune profiling research supporting work like SARS-CoV-2 vaccine development.

Adarza Shifts Focus to SARS-CoV-2 in Anticipation of Protein Biosensor Launch

Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application.

In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many other companies, Adarza found itself having to shift its strategy as the SARS-CoV-2 pandemic shut down non-essential businesses across the economy. Instead of launching the system with its planned focus on immuno-oncology and neurology, the firm has moved to use its technology for immune profiling research supporting work like SARS-CoV-2 vaccine development.

Adarza’s Ziva provides window into immune response to COVID-19 and other pathogens

Adarza Biosystems Inc.’s Ziva platform can simultaneously detect hundreds of proteins, antibodies, or substrates from a single drop of blood, plasma or serum, providing insight into an individual’s immune response. That could be critical for both surveillance and diagnostic purposes as the nation prepares for a likely second wave of the novel coronavirus in the fall when multiple respiratory pathogens will be circulating.

ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING

ROCHESTER, NY and ST LOUIS, MO (Jan. 19, 2017) – Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing. Proceeds from the financing will be used to further expand production capacity in its St. Peters, MO manufacturing facility and fund final development …

ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING Read More »

Event Update

  Join us at the 15th Cytokines & Inflammation Conference, February 6-7, 2017 in San Diego, CA. Booth #6. And check our poster while you’re there: “A Multiplex Panel for Simultaneously Profiling Toxicant Levels and Biological Response Indicators in Serum Samples”.

Senior QC Manager

Adarza BioSystems, Inc. is a venture capital backed biotechnology company developing label-free protein microarray assays based on the Company’s proprietary Arrayed Imaging Reflectometry (AIR™) platform.  Adarza is seeking a Quality Manager to implement our QMS and lead the ISO 9001:2015 certification process.  Reporting to the Head of Missouri Operations, this individual will have an opportunity …

Senior QC Manager Read More »